Interim results with Advanced Tissue Sciences' (ATS) Dermagraft "encouraging"
This article was originally published in Clinica
Executive Summary
Results with Advanced Tissue Sciences' Dermagraft for treatment of diabetic foot ulcers in the first half of some 200 patients to be enrolled in the US trial are "quite encouraging", says president and COO Dr Gail Naughton. The interim results are in line with those of an earlier pivotal trial in which complete wound healing was seen in 50% of Dermagraft patients with no recurrence of ulcers up to 14 months after treatment.